New Veeva China Campaign Manager Drives Precision Omnichannel Marketing for Life Sciences
SHANGHAI, June 12, 2025 – Veeva Systems (NYSE: VEEV) today announced the launch of Veeva China Campaign Manager . As part of Veeva China CRM Suite, this new solution is specifically designed to improve marketing efficiency for pharmaceutical companies operating within China’s unique digital ecosystem by fostering closer alignment between sales and marketing teams.
Veeva China Campaign Manager enhances collaboration and provides greater visibility into campaign execution, enabling real-time adjustments based on performance insights. This ensures that sales and marketing efforts are synchronized for maximum impact. Key features include:
- Integrated Digital Reach for Precision Targeting: Use advanced tagging and segmentation capabilities and ready-to-use digital engagement channels embedded in Veeva China CRM Suite.
- Connected Field and Non-Field Channels: Plan and execute campaigns across a comprehensive range of field and non-field channels. Enable the field team to adjust healthcare professional (HCP) target lists, content sharing, and channel selection, including tailored surveys for capturing valuable feedback.
- Actionable Insights for Marketing: Seamlessly gather insights during the execution of marketing campaigns to improve and optimize aspects such as target coverage, channel selection, and field force execution.
- Goal-Oriented Tracking: Enable holistic view of campaign performance to identify what’s working and optimize strategies for maximum impact.
Veeva China Campaign Manager streamlines the orchestration of non-personal and field force engagement in China’s digital ecosystem, including WeChat service account, WeCom engagements, calls, events, remote meetings, and remote detailing. This ensures pharmaceutical companies can connect with HCPs effectively through their preferred channels.
“To meet the growing demand for more precise omnichannel marketing, pharmaceutical companies in China urgently need intelligent platforms to efficiently execute, track, and optimize their brand strategies,” said Shon Gao, vice president, commercial strategy for Veeva China. “Veeva China Campaign Manager provides these essential capabilities, empowering companies to successfully launch new products, promote multiple brands, and drive portfolio selling strategies.”
Veeva China Campaign Manager is a powerful addition to the well-established Veeva China CRM Suite, selected by more of the Top 20 biopharmas than any other CRM to deliver compliant, customer-centric HCP engagement in China. A testament to Veeva’s strong China innovation capability, Veeva China Campaign Manager, together with other Veeva China CRM Suite components, seamlessly integrates with Veeva PromoMats for content management and Veeva Network for master data management to ensure global governance and compliance.
Veeva China CRM Suite is part of Veeva Commercial Cloud, the global technology foundation for commercial excellence. In addition to China Campaign Manager, Veeva China CRM Suite includes China CRM, China Events Management, Approved WeChat, and China Engage.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.
Lotus Cai
Veeva Systems
